ICU Medical, Inc.
ICUIHealthcareNASDAQMedical Instruments & Supplies · Last scanned Sep 8, 2026
Scan Results
Daily timeframeICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. At a $4.19B market cap, ICU Medical, Inc. ranks as a mid-cap company within healthcare. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products.
Market Cap
$4.19B
Beta
0.76
P/E (TTM)
140.82
P/E (Fwd)
17.37
EPS (TTM)
$1.19
EPS (Fwd)
$9.65
ROE
1.4%
ROA
1.9%
Cash
$302.6M
Total Debt
$1.29B
Free CF
$163.6M
52W Change
28.3%
Annual Financials
Cash vs Debt
Where ICUI stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ICUI finished 17.32% above its 150-day moving average ($144.78) and 16.91% above its 200-day moving average ($145.28). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ICUI overbought or oversold?
At the September 3, 2026 close, ICUI's RSI(14) was 21.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
ICU Medical, Inc. carries $1.29B in total debt against $302.6M in cash reserves — debt is roughly 4.3x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $163.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 1.4%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.9% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $2.28B (2022) to $2.23B (2025).
At over 50x earnings, ICUI carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for ICU Medical, Inc. and its sector.